click below
click below
Normal Size Small Size show me how
P1, top 200, grp 2
Top 200 grp 2
Brand | Generic | Class | Indication | Dose Form | Route | Adult Dose | Pediatric Dose | MOA |
---|---|---|---|---|---|---|---|---|
Aciphex | Rabeprazole | PPI (proton pump inhibitor) | GERD, Duodenal Ulcer Disease | Tablet: 20 mg | Oral | 20-60 mg QD-BID | 12 years and older: 20 mg once daily for 8 weeks.1 1 to 11 years: 15 kg or more: 10 mg once daily for up to 12 weeks. Less than 15 kg: 5 mg once daily for up to 12 weeks; increase to 10 mg if inadequate response | Suppresses gastric secrecion by inhibiting the gastric H+, K+ ATPase at the secretory surface of parietal cells |
Nexium | esomeprazole | PPI (proton pump inhibitor) | GERD, Duodenal Ulcer Disease, Gastric Ulcer | Delayed-release caps: 20 or 40 mg Delayed-release powder for susp: 2.5, 5, 10, 20, 40 mg Powder for inj: 20 or 40 mg | Oral, injection | 20-40 mg QD | 1 MO -1 YO: 0.5mg/kg QD 1-17 YO: 10-20 mg QD for 8 weeks | Suppresses gastric secrecion by inhibiting the gastric H+, K+ ATPase at the secretory surface of parietal cells |
Prevacid | lansoprazole | PPI (proton pump inhibitor) | Duodenal Ulcer Disease, Gastric ULcer, Esophagitis, GERD | Tablets or Solutabs: 15-30 mg | Oral | 15-30 mg QD | 1-12YO: <30kg15mg;>30kg 30mg QD | Suppresses gastric secrecion by inhibiting the gastric H+, K+ ATPase at the secretory surface of parietal cells |
Prilosec | omeprazole | PPI (proton pump inhibitor) | GERD, Duodenal Ulcer Disease, Stress Ulcer, Gastric Ulcer, Esophagitis | Delayed-release Granules for susp: 2.5 or 10 mg Delayed-release Caps: 10, 20, 40 mg Delayed-release OTC Tab: 20 mg | Oral | 20-40 mg QD | 5-20 mg QD | Suppresses gastric secrecion by inhibiting the gastric H+, K+ ATPase at the secretory surface of parietal cells |
Protonix | pantoprazole | PPI (proton pump inhibitor) | GERD, Gastric Hypersecretion | Delayed-release Tab: 20-40 mg Delayed-release granules for susp: 40 mg Powder for Inj: 40 mg | Oral, IV | 40-80 mg QD-BID | >5YO:<40kg-20mg; >40kg-40mg QD | Suppresses gastric secrecion by inhibiting the gastric H+, K+ ATPase at the secretory surface of parietal cells |
Dexilant | dexlansoprazole | PPI (proton pump inhibitor) | Esophagitis, GERD, Pyrosis (heartburn) | Delayed-relase capsule: 30 or 60 mg | Oral | 30-60 mg QD | N/A | Suppresses gastric secrecion by inhibiting the gastric H+, K+ ATPase at the secretory surface of parietal cells |
Welchol | Colesevelam | Bile Acid Sequesterant | Hypercholesterolemia, Hyperlipoproteinemia, Type 2 Diabetes Mellitus | Tablet: 625mg Powder for Susp: 3.75mg | Oral | 3 tabs BID or 6 tabs QD; 1.875 gram packet BID or 3.75 gram packet QD | 10-17 YO: 1.875 gram single-dose packet BID or 3.75 gram packet QD (Not for under 10 yrs) | Binds with bile acids in the intestine to form an insoluble complex that is eliminated in the feces |
Zantac | Ranitidine | Histamine, H2 antagonist | GERD, Duodenal Ulcer Disease, Gastric Ulcer, Indigestion | Syrup: 75mg/5ml or 150mg/10ml Tablets: 75, 150, 300mg Inj. Soln.: 1mg/ml or 25mg/ml Granules for Soln.: 150mg Effervescent Tab: 25 or 150mg | Oral, IV | Oral: 150mg QD-BID IV: 50mg Q6-8 hrs | 2-4 mg/kg/day (oral or IV) | Competitive reversible inhibitor of histamine at H2 receptors |
Zetia | Ezetimibe | Cholesterol Absorption Inhibitor | Hypercholesterolemia, Hyperlipoproteinemia | Tablets: 10mg | Oral | 10mg QD | 10 YO+: 10mg QD | Inhibits absorption of cholesterol at the brush border of the small intestine via the sterol transporter NPC1L1 |
Niaspan | Niacin | Nicotinic Acid | Hyperlipidemia | ER Tablets: 500, 750, 1000mg | Oral | 100-1000mg TID (max of 4500mg/day) | 100-250mg QD (divided into 3 doses) | Precise MOA unknown |
Pepcid | Famotidine | Histamine H2 Antagonist | Duodenal Ulcer, Dyspepsia, Esophagitis, Gastric Ulcer, GERD, H. Pylori Eradication, Multiple Endocrine Adenoma Syndrome, Pyrosis, Systemic Mastocytosis, Zollinger-Ellison Syndrome | Tablets: 20 or 40mg; AC 10mg tablet or gelcap Premixed Inj. Soln.: 10mg/ml, 20mg/50ml Powder For Susp: 40mg/5ml Complete Chew Tab | Oral, IV | 20-160mg QD or BID | 0-16YO: 0.5mg/kg QD or BID | Inhibits the binding of histamine to H2 receptors on the gastric basolateral membrane of parietal cells, reducing basal and nocturnal gastric acid secretions |
Tricor | Fenofibrate | Antilipemic Agent, Fibric Acid | Hypercholesterolemia, hypertriglyceridema | Tablet: 48mg, 145mg | Oral | Hypertriglyceridemia: 48-145mg QD Hypercholesterolemia or mixed dysplipidemia: 145mg QD | safety not established | Agonist of nuclear transcription factor PPar-alpha |
Vytorin | Ezetimibe/Simvastatin | Antilipemic Agent, HMG-CoA Reductase Inhibitor | Hypercholesterolemia, Hyperlipidemia, ASCVD | Tablet: 10mg, 20mg, 40mg, 80mg | Oral | 10-40 mg po qd | 10yrs+ 10-20 mg po qd | sterol transporter inhibitor, HMG-CoA Reductase inhibitor |
Lipitor | Atorvastatin | HMG-CoA Reductase Inhibitor | Hypercholeserolemia & mixed hyperlipidemia, ASCVD | Tablet: 10mg, 20mg, 40mg, 80mg | Oral | 10-80 mg qd | HeHF: 10-17yr(females>1 yr postmenarche): 10mg qd. Max 20mg | HMG-CoA Reductase inhibitor |
Lovaza | Omega-3 ethyl esters | Acyl-CoA Inhibitor | Hypertriglyceridemia | Soft gel Capsule: 1g=1000mg | Oral | 4g qd or 2g bid | N/A | Acyl-CoA Inhibitor |
Mevacor | Lovastatin | Antilipemic agent, HMG-CoA Reductase Inhibitor | Dyslipidemia & 1o prevent of CAD (coronary artery disease), ASCVD | Tablet: 10, 20, 40mg | Oral | 20mg qd w/ evening meal. Max 80mg ASCVD: 40mg qd | Heterozygous familial hypercholesterolemia: 10-17yr LDL reduction <20%: 10 qd w/ evening meal LDL reduction ≥ 20%: 20 qd w/ evening meal Max: 40 mg | HMG-CoA Reductase Inhibitor |
Crestor | Rosuvastatin | HMG-CoA Inhibitor | Hyperlipidemia,Hypertriglyceridemia, Atherosclerosis,Hyperlipoproeteinemia,Hypercholesterolemia,Prophylaxis | Tablets:5,10,20,40 mg | oral | 5-40mg QD | 10-17YO:5-20mg QD | HMG-CoA Reductase inhibitor |
Pravachol | Pravastatin | HMG-CoA Inhibitor | Hyperlipidemia, Hypercholesterolemia, Prophylaxis | Tablets: 10,20,40,80 | oral | 40-80mgQD | 8-13YO:20 mg QD 13-18YO: 40mg QD | HMG-CoA Reductase inhibitor |
Trilipix | Choline Fenofibrate | Antilipemic Agent, Fibric Acid | Hypercholesterolemia, hypertriglyceridema | Capsule Delayed release 45mg and 135mg | Oral | Hypertriglyceridemia: 45-135mg QD Hypercholesterolemia or mixed dysplipidemia: 135mg QD | Safety and efficacy in children have not been established | Agonist of nuclear transcription factor PPar-alpha |
Antara | Fenofibrate | Antilipemic Agent, Fibric Acid | Hypercholesterolemia, hypertriglyceridema | Capsule: 30,90 mg | Oral | Hypertriglyceridemia: 30-90mg QD Hypercholesterolemia or mixed dysplipidemia: 90mg QD | Safety and efficacy in children have not been established | Agonist of nuclear transcription factor PPar-alpha |
Zocor | Simvastatin | HMG-CoA Inhibitor | Heterozygous familial hypercholesterolemia in adolescents (10 to 17 years of age, Hyperlipidemia, Primary and secondary prevention of atherosclerotic cardiovascular disease | Tablet: 5,10,20,40,80mg | Oral | Hyperlipidemia: 5 to 40 mg QD in the evening. Homozygous familial hypercholesterolemia: 40 mg QD in the evening, Prevention of coronary events: 5 to 40 mg QD in the evening | Heterozygous familial hypercholesterolemia: 10 to 17 years of age: 10 to 40 mg QD | HMG-CoA Reductase inhibitor |
Zofran | Ondansetron | Serotonin Receptor Antagonist, 5-HT3 (Antiemetic) | Prevention of nausea and vomiting due to chemo, or post op, or radiotherapy | Tablet Dispersible: 4,8mg Film: 4,8mg | Oral | Cancer,Highly Emetogenic: 24mg 30min before, Moderate Emetogenic: 8mg Bid start 30 before. Radiotherapy: 8mg TID start 1-2 before. Post op: 16mg 1hr prior to anesthesia | Only approved for moderately emetogenic <12 years of age: 8mg BID start 30 min before. 4-11 years of age: 8mg BID start 30 min before. | Serotonin Receptor Antagonist, 5-HT3 (Antiemetic) |